Table 1 Patient (at baseline), treatment and blood sampling characteristics
Patient characteristic | Total dataset |
|---|---|
Categorical variables | n (%) |
No. of patients | 7 (100) |
No. of male patients | 6 (86) |
No. of patients with CVVHD/CVVHDF | 7 (100)/ 3 (43)a |
No. of patients with Cytosorb® | 7 (100) |
No. of samples | 160 (100) |
No. of CytoSorb®-treatments | 20 |
No. of samples during Cytosorb® | 24 (15) |
Continuous parameters [unit] | Median (range) |
CytoSorb®-treatment duration [h] | 6 (1.7–27.9) |
Vancomycin daily dose [mg] | 1380 (240–3000) |
Vancomycin concentration with CytoSorb® [mg/L] | 16.7 (12.4–21.6) |
Vancomycin concentration without CytoSorb® [mg/L] | 20.4 (6.2–33.3) |
Continuous parameters on study day 1 [unit] | Median (range) |
Age [years] | 52 (20–57) |
Weight [kg] | 87 (56–130) |
Serum albumin concentration [g/dL] | 2.4 (1.1–4.2) |
SOFA at day 1 | 17 (15–20) |
Bilirubin concentration [mg/dL] | 6.1 (0.1–31.4) |
IL-6 concentration [pg/mL] | 102 (4.5–554,000) |
CRP concentration [mg/dL] | 7.5 (0.1–49.4) |
Residual diuresis [mL/day] | 0 (0–3550) |
Dialysate flow [L/h] | 2.0 (1.5–3.0) |
Substitute flow [L/h]b | 1.5 (1.5–3.0) |
Blood flow [L/h] | 6.0 (4.8–12) |